top of page

BioNTech settles Covid-19 patent dispute with CureVac, P2


August 8, 2025

Source: The Guardian

Photo / Image Source: Unsplash,


  If the deal is completed, BioNTech will also need to pay GSK an additional $130mn in cash, and 1 per cent royalties on future sales of the relevant vaccines outside of the US.  Recommended Drug prices Trump demands drug companies lower prices before end of September The patent settlement also includes a renegotiation of the partnership with CureVac that will allow GSK to pay lower milestone payments to BioNTech if the deal closes.   Separately, GSK is still pursuing litigation over its own mRNA patents.  BioNTech is also working on a combination of Covid-19 and flu, as well as pursuing shots for other infectious diseases including tuberculosis, herpes and malaria.  But the company is focused on developing new oncology treatments, including using mRNA to create so-called personalised cancer vaccines, which help the immune system recognise and tackle tumours.




How can such practices impact your health? How Why?


COVID Vaccine. Shidonna Raven Garden & Cook, Soaring by Design
COVID Vaccine. Shidonna Raven Garden & Cook, Soaring by Design







Share the wealth of health with your friends and family by sharing this article with 3 people today.


If this article was helpful to you, donate to the Shidonna Raven Garden and Cook E-Magazine Today. Thank you in advance.





Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
  • YouTube
  • Pinterest
  • Facebook
  • Twitter
  • Instagram
  • Pinterest

Shidonna Raven (TM)
Copyright - All Rights Reserved
Proudly created with Wix.com

bottom of page